S outh African authorities are examining Johnson & & Johnson and its Janssen subsidiary over “extreme rates” of a lifesaving tuberculosis drug, the current imbroglio to swallow up the business over its medication.
In a short declaration, the South African Competitors Commission validated that it lodged a grievance previously today versus the healthcare giant over its TB medication, bedaquiline, which is likewise offered under the Sirturo brand. The regulator did not offer any information besides to state it knows recommending a “affordable suspicion” the business might likewise have actually taken part in “exclusionary practices.”
We asked J&J for remark and will upgrade you appropriately.
Get limitless access to acclaimed journalism and special occasions.